

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 40524

Manuscript Type: MINIREVIEWS

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Marisi G *et al.* Sorafenib markers in HCC

Giorgia Marisi, Alessandro Cucchetti, Paola Ulivi, Matteo Canale, Giuseppe Cabibbo, Leonardo Solaini, Francesco G Foschi, Serena De Matteis, Giorgio Ercolani, Martina Valgiusti, Giovanni L Frassinetti, Mario Scartozzi, Andrea Casadei Gardini

Abstract

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies

Match Overview

1	Internet 99 words crawled on 30-Jun-2017 www.wjgnet.com	2%
2	Crossref 81 words Andrea Casadei Gardini , Giovanni Luca Frassinetti , Francesco Giuseppe Foschi , Giorgio Ercolani , Paola Ulivi . "S	2%
3	Internet 78 words crawled on 08-Nov-2017 www.impactjournals.com	2%
4	Internet 61 words crawled on 17-Dec-2015 office.wjgnet.com	1%
5	Crossref 59 words Jorge A. Marrero , Masatoshi Kudo , Alan P. Venook , Sheng-Long Ye et al. "Observational registry of sorafenib us...	1%
6	Internet 54 words crawled on 04-May-2016 hepatitisresearchandnewsupdates.blogspot.co.nz	1%
7	Crossref 47 words Hwi Young Kim , Dong Hyeon Lee , Jeong-Hoon Lee , Young Youn Cho , Eun Ju Cho , Su Jong Yu , Yoon Jun Kim , J	1%
8	Internet 45 words crawled on 25-Mar-2018 journals.sagepub.com	1%
9	Crossref 39 words Massimo Iavarone . "Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicen	1%

About 138,000 results (0.54 seconds)

Prognostic factors and predictors of sorafenib benefit ... - Science Direct
<https://www.sciencedirect.com/science/article/pii/S0168827817321347>
by J Bruix - 2017 - Cited by 26 - Related articles

Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival ... To assess **prognostic factors** for **HCC** and **predictive** factors of **sorafenib** benefit, we ... Overall, the 5-year survival rate for patients with **HCC** is less than 20%. ... [9], [10] Briefly, patients enrolled in both studies had unresectable **HCC** and had not ...

Predictive factors in patients with hepatocellular carcinoma receiving ...
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332888/> ▾
by H Nishikawa - 2017 - Cited by 3 - Related articles

Feb 10, 2017 - The median OS time was 0.68 **years**, while the median PFS time was 0.24 **years**. ... Keywords: **Hepatocellular carcinoma**, **Sorafenib**, Clinical outcomes, **Predictive** ... chemotherapeutic agent for unresectable **HCC**. **Prognostic factors** at **There** were **no** significant continuous variables linked to PFS in this ...

Early prediction of survival in hepatocellular carcinoma patients ...
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787783/>
by XC Meng - 2018 - Related articles

Jan 28, 2018 - Core tip: **There** are **no** clinical data/**markers** to early predict improved ... 75 **years** of age; (2) having **an** Eastern Cooperative Oncology Group (ECOG) PVT has a profound adverse effect on **prognosis**, resulting in a very alone in **predicting** survival in **HCC** patients treated with TACE plus **sorafenib**.

Comparison of five staging systems in hepatocellular carcinoma ...
<https://www.spandidos-publications.com/mco/4/4/515>
by M Endo - 2016 - Cited by 2 - Related articles

Jan 28, 2016 - Of these **prognostic** systems for **HCC**, the Japan Integrated Staging (JIS) system, the ... **predictive factors** of responders to **sorafenib**

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 168,000 条结果 (用时 0.54 秒)

Prognostic factors and predictors of sorafenib benefit ... - Science Direct

<https://www.sciencedirect.com/science/article/pii/S0168827817321347> - 翻译此页

作者: J Bruix - 2017 - 被引用次数: 28 - 相关文章

Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival ... To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we ... Overall, the 5-year survival rate for patients with HCC is less than 20%. ... [9], [10] Briefly, patients enrolled in both studies had unresectable HCC and had not ...

Predictive factors in patients with hepatocellular carcinoma receiving ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332888/> - 翻译此页

作者: H Nishikawa - 2017 - 被引用次数: 3 - 相关文章

2017年2月10日 - The median OS time was 0.68 years, while the median PFS time was 0.24 years. ... Keywords: Hepatocellular carcinoma, Sorafenib, Clinical outcomes, Predictive ... chemotherapeutic agent for unresectable HCC. Prognostic factors at There were no significant continuous variables linked to PFS in this ...

Hepatocellular carcinoma: a review - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063561/> - 翻译此页

作者: J Balogh - 2016 - 被引用次数: 112 - 相关文章

2016年10月5日 - HCC is an aggressive cancer that occurs in the setting of cirrhosis and ... HCC can be prevented if there are appropriate measures taken, ... with a 2.5–3 times increased risk of developing HCC in 8–10 years follow-up. markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence.

Prognostic factors and predictors of sorafenib benefit in patients with ...

[https://www.journal-of-hepatology.eu/article/S0168-8278\(17\)32134-7/pdf](https://www.journal-of-hepatology.eu/article/S0168-8278(17)32134-7/pdf) - 翻译此页

作者: J Bruix - 2017 - 被引用次数: 30 - 相关文章

2017年7月4日 - Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND ... tors for HCC and predictive factors of sorafenib benefit, we.

Comparison of five staging systems in hepatocellular carcinoma ...

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 168,000 条结果 (用时 0.54 秒)

Prognostic factors and predictors of sorafenib benefit ... - Science Direct

<https://www.sciencedirect.com/science/article/pii/S0168827817321347> - 翻译此页

作者: J Bruix - 2017 - 被引用次数: 28 - 相关文章

Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival ... To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we ... Overall, the 5-year survival rate for patients with HCC is less than 20%. ... [9], [10] Briefly, patients enrolled in both studies had unresectable HCC and had not ...

Predictive factors in patients with hepatocellular carcinoma receiving ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332888/> - 翻译此页

作者: H Nishikawa - 2017 - 被引用次数: 3 - 相关文章

2017年2月10日 - The median OS time was 0.68 years, while the median PFS time was 0.24 years. ... Keywords: Hepatocellular carcinoma, Sorafenib, Clinical outcomes, Predictive ... chemotherapeutic agent for unresectable HCC. Prognostic factors at There were no significant continuous variables linked to PFS in this ...

Hepatocellular carcinoma: a review - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063561/> - 翻译此页

作者: J Balogh - 2016 - 被引用次数: 112 - 相关文章

2016年10月5日 - HCC is an aggressive cancer that occurs in the setting of cirrhosis and ... HCC can be prevented if there are appropriate measures taken, ... with a 2.5–3 times increased risk of developing HCC in 8–10 years follow-up. markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence.

Prognostic factors and predictors of sorafenib benefit in patients with ...

[https://www.journal-of-hepatology.eu/article/S0168-8278\(17\)32134-7/pdf](https://www.journal-of-hepatology.eu/article/S0168-8278(17)32134-7/pdf) - 翻译此页

作者: J Bruix - 2017 - 被引用次数: 30 - 相关文章

2017年7月4日 - Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND ... tors for HCC and predictive factors of sorafenib benefit, we.

Comparison of five staging systems in hepatocellular carcinoma ...